Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.40 |
| ▸ | MERTK | Q12866 | 6/20 | 0.40 |
| ▸ | KDR | P35968 | 9/20 | 0.39 |
| ▸ | BRAF | P15056 | 8/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371154 | 0.86 | KDR (0.47) | KDRBRAF | |
| SCHEMBL5358853 | 0.86 | KDR (0.45) | AXLMERTKKDRBRAFMAPK14 | |
| SCHEMBL1891087 | 0.86 | AXL (0.44) | AXLMERTKKDRBRAFMAPK14 | |
| SCHEMBL1892285 | 0.82 | YAP1 (0.45) | AXLMERTKKDRBRAFJAK2 | |
| SCHEMBL4333203 | 0.81 | MEN1 (0.40) | AXLMERTKKDRBRAFMAPK14 | |
| SCHEMBL14423600 | 0.78 | JAK2 (0.46) | KDRBRAFMAPK14JAK2TYK2 | |
| SCHEMBL4339407 | 0.73 | KDR (0.41) | KDRBRAFMAPK14 | |
| SCHEMBL1894434 | 0.73 | KDR (0.51) | KDRBRAF | |
| SCHEMBL5370566 | 0.73 | KDR (0.48) | KDRBRAFMAPK14 | |
| SCHEMBL12503676 | 0.73 | YAP1 (0.46) | AXLMERTKKDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | AXL 515/4885MERTK 2898/4885KDR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.